During his studies, Anders Dinesen developed and investigated several different multifunctional drug designs against cancer and COVID-19. Albumin is used as a scaffold to assemble multiple functional therapeutic and diagnostic moieties, producing one single improved multifunctional drug. In addition to acting as a common scaffold, albumin also provides the construct with extended circulation in the body, thereby, potentially prolonging the therapeutic effect.
The developed constructs highlight the versatility and favourable properties of multifunctional drugs and albumin as a carrier for these next-generation drugs, which may allow therapy of diseases that have so far avoided effective treatment.

The PhD degree was completed at the Interdisciplinary Nanoscience Center (iNANO), Faculty of Natural Sciences, Aarhus University.

This summary was prepared by the PhD student.

Time: Friday 3^rd of May 2024 at 13:15
Place: Building 1593, room 012, iNANO auditorium, iNANO, Gustav Wieds vej 14, Aarhus University, 8000 Aarhus C.
Title of dissertation: Albumin as a Multi-Modal Functionalisation Scaffold for Next-Generation Drug Designs
Contact information: Anders Dinesen, e-mail: Dinesen@inano.au.dk

Members of the assessment committee:
Professor Dan Peer, Cell research and Immunology Department, The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Israel

Associate Professor Marco Donia, Center for Cancer Immune Therapy (CCIT), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Senior Researcher Morten Foss, iNANO, Aarhus University, Denmark (chair)

Main supervisor:
Associate Professor Ken Howard, iNANO, Aarhus University, Denmark

Language: The PhD dissertation will be defended in English

The defence is public.